Clinical trial
Adaptive COVID-19 Treatment Trial (ACTT)
NCT04280705 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT04280705 |
|---|---|
| Title | Adaptive COVID-19 Treatment Trial (ACTT) |
| Official title | A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | COVID-19 |
| Intervention type | Drug, Other |
| Interventions | Placebo, Remdesivir |
| Enrollment | 1,062 |
| Start date | Feb 21, 2020 |
| Primary completion | May 21, 2020 |
| Completion | May 21, 2020 |
| First posted | Feb 21, 2020 |
| Last update posted | Mar 14, 2022 |
| Countries | Denmark, Germany, Greece, Japan, Mexico, Singapore, South Korea, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: